This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
16 Sep 2024

Linnea is compliant with the new CBD monograph issued by the European pharmacopoeia

CBD Laboratory

Linnea is proud to comply with the new CBD monograph issued by the European Pharmacopoeia. This monograph is applicable for medical prescriptions, pharmacy compounding, clinical trials, pharmaceutical development, and registrations.

The final draft was published in January 2024, and starting from July 2024, the rules and requirements detailed in the official text will be obligatory for all member states. Previous guidelines, such as the DAC monograph on CBD, will be superseded by a unified set of specifications.

These specifications include:

- Functionality-related characteristics: these are crucial for the quality of a medicinal product and the consistency of its manufacturing process.- Definition: the monograph specifies the content (98.0% to 102.0%) and clarifies that CBD is isolated from the Cannabis sativa L. plant.
- Characters:
- Appearance
- Solubility
- Identification:
- Infrared absorption spectrophotometry
- Specific optical rotation
- Storage
- Labelling
- Impurities: impurities are specified, cataloged, and acceptance criteria are provided for each.

Mentioned Companies
Linnea SA
View company profile